Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplant. 2015 Sep;50(9):1250-2. doi: 10.1038/bmt.2015.120. Epub 2015 Jun 8.

Authors

S Watanabe¹, Y Waseda¹, H Kimura¹, H Takato¹, K Ohata², Y Kondo², K Kasahara¹, S Nakao²

Affiliations

¹ Department of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan.
² Department of Hematology, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan.

PMID: 26052911
DOI: 10.1038/bmt.2015.120

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allografts
Bronchiolitis Obliterans / drug therapy*
Bronchiolitis Obliterans / etiology
Female
Hematopoietic Stem Cell Transplantation*
Humans
Imatinib Mesylate / administration & dosage*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged

Substances

Imatinib Mesylate